Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Czech Republic-based Zentiva Pharma, a generics and over-the-counter medicines company that is wholly-owned by private equity ...

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the first generics company to receive approval for Liraglutide in a major ...

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...